Dociparstat Sodium

Summary

Dociparstat Sodium (CHEMBL3990006) is a phase-3 clinical-stage unknown; indicated across 2 conditions including acute myeloid leukemia and exocrine pancreatic carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3990006
Name	Dociparstat Sodium
Type	Unknown
Max phase	3

Also known as: Dociparstat sodico, Dociparstat sodique, Dociparstat sodium, GM-1892, ODSH, DOCIPARSTAT SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1	2
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04389840	PHASE2/PHASE3	TERMINATED	Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
NCT00457951	PHASE2	TERMINATED	A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD
NCT02873338	PHASE2	COMPLETED	Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
NCT02056782	PHASE1	COMPLETED	A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia
NCT02164097	PHASE1	TERMINATED	ODSH + ICE Chemotherapy in Pediatric Solid Tumors
NCT01843634	EARLY_PHASE1	COMPLETED	Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).